What is the role of cytokine immunotherapy in the treatment of clear cell renal cell carcinoma (CCRCC)?

Updated: Mar 11, 2019
  • Author: Ronald J Cohen, MB, BCh, PhD, FRCPA, FFPATH; Chief Editor: Liang Cheng, MD  more...
  • Print
Answer

Answer

Approximately 20% of patients with metastatic clear cell renal cell carcinoma (CCRCC) respond to cytokine immunotherapy with interleukin-2, although the median survival is increased only from 10 months to 34 months. [55, 99] Clinical trials show slightly more promising results for treatment of metastatic CCRCC with antiangiogenic agents (sunitinib, sorafenib; see the image below) and mTOR kinase inhibitors (temsirolimus), which have been approved for treatment of RCC in the United States and Europe. [99]

Clear cell renal cell carcinoma showing extensive Clear cell renal cell carcinoma showing extensive necrosis following treatment with the antiangiogenic agent sunitinib.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!